GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, has reported new pre-clinical data demonstrating the inhibitory effects of GFT505 on the proliferation of cancer cells of different origins.

GENFIT previously launched a major research programme on the mechanism of action and the cellular signaling pathways implicated in GFT505 treatment. In this context, GENFIT reports new data concerning the potential protective effects of GFT505 in different types of cancer.

In these studies, the effects of GFT505 on the proliferation of 21 human cancer cell lines were evaluated in vitro. The cell lines used originated from different types of cancer: meningiomas, leukaemia, lung cancer, gastrointestinal tumours, pancreatic cancer, myeloproliferative disorders, skin cancer (dermatofibrosarcoma), colon cancer, breast cancer, thyroid cancer, and prostate cancer. GFT505 blocks proliferation in the majority of these cell types, suggesting protective in numerous types of tumour. These results support a new international patent application on the use of GFT505 in the treatment of several cancer types.

Commenting on this data, Dr Robert Walczak, director of Research at GENFIT, declared: “GFT505 is being developed in NASH with the aim of preventing not only the development of liver cirrhosis but also reducing the associated risk of liver cancer. This new data completes that previously obtained in the liver, and further strengthens the potential of GFT505 in the field of oncology.”